Log in

Removal of DATA Waiver (X-Waiver) Requirement

February 01, 2023 1:24 PM | Judy Pfeiffer (Administrator)

The most current updates will be here: Removal of DATA Waiver (X-Waiver) Requirement | SAMHSA

Update on 1/25/2023:

·         Section 1262 of the Consolidated Appropriations Act, 2023 (also known as Omnibus bill), removes the federal requirement for practitioners to submit a Notice of Intent (have a waiver) to prescribe medications, like buprenorphine, for the treatment of opioid use disorder (OUD). With this provision, and effective immediately, SAMHSA will no longer be accepting NOIs (waiver applications).

All practitioners who have a current DEA registration that includes Schedule III authority, may now prescribe buprenorphine for Opioid Use Disorder in their practice if permitted by applicable state law and SAMHSA encourages them to do so. SAMHSA and DEA are actively working on implementation of a separate provision of the Omnibus related to training requirements for DEA registration that becomes effective in June 2023. Please continue to check this webpage for further updates and guidance.

275 Annual Report

275 Annual Reports are no longer required or being accepted.

Current Updates, use this link:

Removal of DATA Waiver (X-Waiver) Requirement | SAMHSA


Non-members interested in CME must create a profile with AOAAM. Subscribe now or Join Us to receive the full benefits of membership.

Latest News  read more

The 8-hour MOUD Training

Hot Topics in

Addiction Medicine

On-demand CME

- Live CME

The mission of the American Osteopathic Academy of Addiction Medicine is to improve the health of individuals and families burdened with the disease of addiction.

Powered by Wild Apricot Membership Software